Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antigenics Inc.
Antigenics Receives NASDAQ Delisting Notice
January 11th, 2009
Antigenics Inc. (NASDAQ: AGEN) announced that it received a letter, as expected, from the Listing Qualifications Staff of The NASDAQ Stock Market LLC (the “Staff”) indicating that it had not regained compliance with Marketplace Rule 4450(b)(1)(A), requiring a minimum $50 million market value of listed securities for continued inclusion on The NASDAQ Global Market. The Staff has indicated that the company’s common stock is subject to delisting unless the company requests a hearing before a NASDAQ Listing Qualifications Panel (the “Panel”). Antigenics intends to request a hearing before the Panel to present its plan to maintain continued listing. The company’s shares will...
Source: Pharma Investments, Ventures & Law Weekly (2009-01-11)
|
